Targeting FGFR alterations in cholangiocarcinoma and other solid tumours: A new frontier in personalised medicine - European Medical Journal

This content is intended for healthcare professionals only

Please confirm you do not reside in the following countries: The UK, Spain and Portugal.

Continue

Targeting FGFR alterations in cholangiocarcinoma and other solid tumours: A new frontier in personalised medicine

Oncology
  • Originally presented at ESMO Congress 2022, Incyte’s satellite symposium featured educational presentations from an esteemed faculty of experts including Professor Juan Valle (Co-chair; UK), Dr David Malka (Co-chair; France), Professor Filippo de Braud (Italy), Dr Angela Lamarca (Spain) and Dr Antoine Hollebecque (France).
  • The faculty discussed key cholangiocarcinoma (CCA) topics including the challenges associated with diagnosing CCA, how molecular profiling and the multidisciplinary team approach can be optimised and recent updates to international clinical practice guidelines for biliary tract cancer.
  • An overview of FGFR inhibition in patients with CCA and other solid tumours was presented, including results from the final analysis of FIGHT-202, a Phase 2 open-label, single-arm study evaluating the efficacy and safety of pemigatinib in patients with previously treated, locally advanced or metastatic CCA (NCT02924376).

This educational symposium was originally presented at ESMO Congress 2022 and was developed and funded by Incyte Biosciences International Sàrl.

EU/PEMA/NP/22/0032
Date of preparation: September 2022
© 2022, Incyte. All rights reserved. The Incyte logo is a registered trademark of Incyte

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given